» Articles » PMID: 12450548

Liquid Chromatography-mass Spectrometry Method for the Analysis of the Anti-cancer Agent Capecitabine and Its Nucleoside Metabolites in Human Plasma

Overview
Publisher Elsevier
Date 2002 Nov 27
PMID 12450548
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

A reversed-phase high-performance liquid chromatography method with electrospray ionization and mass spectral detection is described for the determination of capecitabine, 5'-deoxy-5-fluorocytidine and 5'-deoxy-5-fluorouridine in human plasma with 5-chloro-2'-deoxyuridine as the internal standard. An on-line sample clean-up procedure allows dilution of the plasma sample with the initial mobile phase. The linear dynamic range is 0.0500-10.0 microgram/ml for capecitabine, and 0.0500-25.0 microgram/ml for the metabolites, 5'-deoxy-5-fluorocytidine and 5'-deoxy-5-fluorouridine, respectively. This method has been used to analyze plasma samples from patients receiving capecitabine in combination with oxaliplatin.

Citing Articles

A novel approach to the application of hexagonal mesoporous silica in solid-phase extraction of drugs.

Farjadian F, Azadi S, Mohammadi-Samani S, Ashrafi H, Azadi A Heliyon. 2018; 4(11):e00930.

PMID: 30456326 PMC: 6234517. DOI: 10.1016/j.heliyon.2018.e00930.


Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.

Rudek M, Connolly R, Hoskins J, Garrett-Mayer E, Jeter S, Armstrong D Breast Cancer Res Treat. 2013; 139(1):135-43.

PMID: 23588952 PMC: 3673300. DOI: 10.1007/s10549-013-2516-z.


Use of capecitabine in management of early colon cancer.

Hameed H, Cassidy J Cancer Manag Res. 2011; 3:295-9.

PMID: 21931503 PMC: 3173019. DOI: 10.2147/CMR.S12704.


The achievement of mass balance by simultaneous quantification of floxuridine prodrug, floxuridine, 5-fluorouracil, 5-dihydrouracil, α-fluoro-β-ureidopropionate, α-fluoro-β-alanine using LC-MS.

Tsume Y, Provoda C, Amidon G J Chromatogr B Analyt Technol Biomed Life Sci. 2011; 879(13-14):915-20.

PMID: 21450537 PMC: 3086577. DOI: 10.1016/j.jchromb.2011.02.045.


A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer.

Ma W, Herman J, Jimeno A, Laheru D, Messersmith W, Wolfgang C Transl Oncol. 2010; 3(6):373-9.

PMID: 21151476 PMC: 3000462. DOI: 10.1593/tlo.10196.